Evaluation of Cold Sore Treatments on UV Induced Cold Sores

This study has been completed.
Cliantha Research Ltd.
Norwich Clinical Research Associates Ltd.
Information provided by (Responsible Party):
Beech Tree Labs, Inc.
ClinicalTrials.gov Identifier:
First received: July 15, 2013
Last updated: August 14, 2015
Last verified: August 2015
The purpose of this study is to determine if a new drug treatment is effective to block the development of a cold sore lesion following Ultra Violet (UV) exposure.

Condition Intervention Phase
Oral Herpes Simplex
Drug: Matching Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Cold Sore Treatments on UV Induced Cold Sores

Resource links provided by NLM:

Further study details as provided by Beech Tree Labs, Inc.:

Primary Outcome Measures:
  • Block the symptomatic sequence of a lesion of oral herpes simplex outbreak [ Time Frame: 14 days ] [ Designated as safety issue: No ]
    Visual examination of cold sores by trained evaluator and subject self assessment after exposure to UV.

Enrollment: 305
Study Start Date: July 2013
Study Completion Date: February 2015
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Matching Placebo
Matching Placebo
Drug: Matching Placebo
Sublingual micro dosing of placebo for 7 days
Experimental: BTL-TML-HSV
Experimental Product
Sublingual micro dosing of BTL-TML-HSV for 7 days


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical history of recurrent cold sores averaging 2 or more episodes per year
  • UV exposure is known to cause a cold sore outbreak

Exclusion Criteria:

  • History of abnormal reactions to sunlight
  • Used antiviral therapy directly prior to entering study
  • Any other condition which in the opinion of the Investigator may affect the results or place the subject at undue risk.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01902303

United States, Florida
Hill Top Research
St. Petersburg, Florida, United States, 33714
United States, Ohio
Hill Top Research
Cincinnati, Ohio, United States, 45242
United States, South Carolina
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, United States, 29464
Sponsors and Collaborators
Beech Tree Labs, Inc.
Cliantha Research Ltd.
Norwich Clinical Research Associates Ltd.
Study Director: John McMichael, PhD President, Beech Tree Labs, Inc.
  More Information

No publications provided

Responsible Party: Beech Tree Labs, Inc.
ClinicalTrials.gov Identifier: NCT01902303     History of Changes
Other Study ID Numbers: BTL - 2013-06-0161  HTR - 13-131178 
Study First Received: July 15, 2013
Last Updated: August 14, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Beech Tree Labs, Inc.:
Herpes Labialis
Herpes Simplex
Ultra Violet (UV) Induced

Additional relevant MeSH terms:
Herpes Simplex
Stomatitis, Herpetic
DNA Virus Infections
Herpesviridae Infections
Mouth Diseases
Skin Diseases
Skin Diseases, Infectious
Skin Diseases, Viral
Stomatognathic Diseases
Virus Diseases

ClinicalTrials.gov processed this record on February 04, 2016